Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Open access
Maher, Toby M, Tudor, Veronica A, Saunders, Peter, Gibbons, Michael A, Fletcher, Sophie V, Denton, Christopher P, Hoyles, Rachel K, Parfrey, Helen, Renzoni, Elisabetta A, Kokosi, Maria, Wells, Athol U, Ashby, Deborah, Szigeti, Matyas, Molyneaux, Philip L, Akil, Mohammed, Babalis, Daphne, Chaudhuri, Nazia, Chua, Felix, Data, Arnab, Desai, Dhananjay, Dubey, Shrish, Dwyer, Natalie, Flather, Marcus, Fordham, Richard, Grossi Sampedro, Carlota, Hall, Frances, Jakupovic, Ira, Keir, Gregory, Patel, Bipen, Penn, Henry, Rajasekaran, Arvind, Spencer, Lisa G, Tsipouri, Vicky, Wu, Zhe, Xydopoulos, Georgio, Zanghelini, Fernando·2023·The Lancet Respiratory Medicine

Abstract

Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue disease (CTD), but has not been studied in clinical trials. This study aimed to assess whether rituximab is superior to cyclophosphamide as a treatment for severe or progressive CTD associated ILD. Methods We conducted a randomised, double-blind, double-dummy, phase 2b trial to assess the superiority of rituximab compared with cyclophosphamide. Patients aged 18–80 years with severe or progressive ILD related to scleroderma, idiopathic inflammatory myositis, or mixed CTD, recruited across 11 specialist ILD or rheumatology centres in the UK, were randomly assigned (1:1) to receive rituximab (1000 mg at weeks 0 and 2 intravenously) or cyclophosphamide (600 mg/m 2 body surface area every 4 weeks intravenously for six doses). The primary endpoint was rate of change in forced vital capacity (FVC) at 24 weeks compared with baseline, analysed using a mixed-effects model with random intercepts, adjusted for baseline FVC and CTD type. Prespecified secondary endpoints reported in this Article were change in FVC at 48 weeks versus baseline; changes from baseline in 6 min walk distance, diffusing capacity of the lung for carbon monoxide (DL CO ), physician-assessed global disease activity (GDA) score, and quality-of-life scores on the St George's Respiratory Questionnaire (SGRQ), King's Brief Interstitial Lung Disease (KBILD) questionnaire, and European Quality of Life Five-Dimension (EQ-5D) questionnaire at 24 and 48 weeks; overall survival, progression-free survival, and time to treatment failure; and corticosteroid use. All endpoints were analysed in the modified intention-to-treat population, which comprised all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT01862926). Findings Between Dec 1, 2014, and March 31, 2020, we screened 145 participants, of whom 101 participants were randomly allocated: 50 (50%) to receive cyclophosphamide and 51 (50%) to receive rituximab. 48 (96%) participants in the cyclophosphamide group and 49 (96%) in the rituximab group received at least one dose of treatment and were included in analyses; 43 (86%) participants in the cyclophosphamide group and 42 (82%) participants in the rituximab group completed 24 weeks of treatment and follow-up. At 24 weeks, FVC was improved from baseline in both the cyclophosphamide group (unadjusted mean increase 99 mL [SD 329]) and the rituximab group (97 mL [234]); in the adjusted mixed-effects model, the difference in the primary endpoint at 24 weeks was –40 mL (95% CI –153 to 74; p=0·49) between the rituximab group and the cyclophosphamide group. KBILD quality-of-life scores were improved at 24 weeks by a mean 9·4 points (SD 20·8) in the cyclophosphamide group and 8·8 points (17·0) in the rituximab group. No significant differences in secondary endpoints were identified between the treatment groups, with the exception of change in GDA score at week 48, which favoured cyclophosphamide (difference 0·90 [95% CI 0·11 to 1·68]). Improvements in lung function and respiratory-related quality-of-life measures were observed in both treatment groups. Lower corticosteroid exposure over 48 weeks of follow-up was recorded in the rituximab group. Two (4%) of 48 participants who received cyclophosphamide and three (6%) of 49 who received rituximab died during the study, all due to complications of CTD or ILD. Overall survival, progression-free survival, and time to treatment failure did not significantly differ between the two groups. All participants reported at least one adverse event during the study. Numerically fewer adverse events were reported by participants receiving rituximab (445 events) than those receiving cyclophosphamide (646 events). Gastrointestinal and respiratory disorders were the most commonly reported adverse events in both groups. There were 62 serious adverse events of which 33 occurred in the cyclophosphamide group and 29 in the rituximab group. Interpretation Rituximab was not superior to cyclophosphamide to treat patients with CTD-ILD, although participants in both treatment groups had increased FVC at 24 weeks, in addition to clinically important improvements in patient-reported quality of life. Rituximab was associated with fewer adverse events. Rituximab should be considered as a therapeutic alternative to cyclophosphamide in individuals with CTD-ILD requiring intravenous therapy. Funding Efficacy and Mechanism Evaluation Programme (Medical Research Council and National Institute for Health Research, UK).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(22)00359-9

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 290

Metadata

Authors
Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., Wells, A. U., Ashby, D., Szigeti, M., Molyneaux, P. L., Akil, M., Babalis, D., Chaudhuri, N., Chua, F., Data, A., Desai, D., Dubey, S., Dwyer, N., Flather, M., Fordham, R., Grossi Sampedro, C., Hall, F., Jakupovic, I., Keir, G., Patel, B., Penn, H., Rajasekaran, A., Spencer, L. G., Tsipouri, V., Wu, Z., Xydopoulos, G., & Zanghelini, F.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2023-01
Volume
11
Issue
1
Pages
45-54
ISSN
2213-2600 (ISSN-L)
OpenAlex
W4308789438
Cited by
290
References
38
FWCI
33.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. https://app.cochat.ai/papers/10.1016/s2213-2600(22)00359-9
The paper
Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., Wells, A. U., Ashby, D., Szigeti, M., Molyneaux, P. L., Akil, M., Babalis, D., Chaudhuri, N., Chua, F., Data, A., . . . Zanghelini, F. (2023). Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(22)00359-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.